Tissue Factor Pathway Inhibitor (TFPI)

Dystrophin is a rod-shaped cytoskeletal protein that connects the intercellular cytoskeleton to the extracellular matrix through an actin-associated glycoprotein complex. This property enables Dystrophin to play a role in sarcolemmal stability during muscle contraction and prevent contraction damage. Dystrophin also mediates cell signaling, such as mechanotransduction and cell adhesion. However, Dystrophin deficiency or mutation (producing internally truncated Dystrophin) will become a predisposing factor for Duchenne muscular dystrophy (DMD). In the muscle tissue of mild and asymptomatic patients, a large number of alternative Dystrophin splicing protein products can be detected. Currently, the methods for restoring Dystrophin mutations rely on virus-mediated restoration or exon skipping. Exon skipping uses antisense oligonucleotides to induce alternative splicing, bypassing the mutated exon to restore the protein reading frame, and converting DMD mutations to Becker muscular dystrophy (BMD) protein mutations.
Dystrophin-related proteins can be divided into three groups (according to subcellular localization): (1) α-dystroglycan located outside the cell; (2) β-dystroglycan, sarcoglycans, and sarcospan located on the plasma membrane; (3) Dystrophin, dystrobrevin, syntrophins, and neuronal nitric oxide synthase located inside the cell. Dystrophin has four major functional domains: the actin-binding amino-terminal domain (ABD1), the central rod domain, the cysteine-rich domain, and the carboxyl terminus. Dystrophin interacts with tubulin and acidic actin filaments through the rod domain, so Dystrophin mutations not only lead to progressive loss of muscle tissue and function, but also cause cardiomyopathy[1][2][3].

By Effects: Inhibitor (6)
共 6种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
ARC19499
BAX499

ARC19499 是一种核酸适配体,能特异性结合组织因子通路抑制剂(TFPI),阻断 TFPI 对 factor Xa 和 TF/factor VIIa 复合物的抑制作用,从而纠正血友病 A 和 B 血浆中的凝血酶生成并恢复凝血。

1350667-54-7
Inhibitor
ARC19499
ARC19499 sodium
BAX499 sodium

ARC19499 sodium 是一种核酸适配体,与组织因子通路抑制剂(TFPI)特异性结合,阻断 TFPI 对 factor Xa 和 TF/factor VIIa 复合物的抑制作用,从而纠正血友病 A 和 B 血浆中的凝血酶生成并恢复凝血。

Inhibitor
99.40%
ARC19499 sodium
ARC19499 sodium scrambled negative control

ARC19499 sodium scrambled negative control 是 ARC19499 sodium 的乱序阴性对照。

Inhibitor
ARC19499 sodium scrambled negative control
MG1113A

MG1113A 是一种靶向 TFPI 的人类单克隆抗体 (mAb),可用于血友病的研究。

Inhibitor
MG1113A
Befovacimab
贝弗西单抗; BAY 1093884

Befovacimab (BAY 1093884) 是一种能够结合组织因子通路抑制剂 (TFPI) 的全人源单克隆 IgG2 抗体,可用于血友病 A/B 的研究。

2156634-62-5
Inhibitor
97.31%
贝弗西单抗
Marstacimab
马塔西单抗; PF-06741086

Marstacimab (PF-06741086) 是一种抗组织因子通路抑制剂 (TFPI) 单克隆抗体,可用于血友病的研究。

1985638-39-8
Inhibitor
96.27%
马塔西单抗

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础